Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff of these organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund. A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011. With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position. On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million). Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network. The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Forcite Helmet Systems Pty Ltd, established in 2013 and located in Haymarket, Australia, specializes in the production of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation capabilities, intercom functionality, and active noise-cancelling technology. By utilizing sensor technology and the Forcite Command software platform, the company aims to significantly improve the safety of motorcyclists, addressing the challenges posed by the lack of standard safety equipment in motorcycles compared to modern vehicles. The use of lightweight carbon fiber further contributes to the innovative design and performance of their helmets, making motorcycling safer and more connected.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Wildlife Drones Pty. Ltd., founded in 2016 and based in Macquarie, Australia, specializes in designing and developing advanced animal radio-tracking systems utilizing drones. The company addresses the challenges faced by wildlife researchers in tracking the movements of radio-tagged animals, particularly those that are highly mobile. Traditional ground-based tracking often requires elevated positions, making it labor-intensive and costly, as it may involve using helicopters or planes to receive clear signals. Wildlife Drones' innovative technology enhances the quality and quantity of radio-tracking data by allowing drones to reach greater altitudes. This capability supports a range of applications for wildlife researchers, conservationists, and environmental consultants, including the monitoring of endangered species, tracking invasive species, and locating livestock on remote properties, thereby aiding efforts to minimize environmental impact.
OccuRx Pty. Ltd., a biopharmaceutical company, engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. It has a library of chemical compounds with potent anti-inflammatory and anti-fibrotic properties to treat diabetic retinopathy and other fibrotic diseases of the retina. The company was incorporated in 2013 and is based in Melbourne, Australia.
Morse Micro PTY. LTD. is an Australian company specializing in the design and development of wireless chip technology, particularly focused on Wi-Fi solutions for the Internet of Things (IoT). Founded in 2016 and headquartered in Eveleigh, Australia, the company offers Wi-Fi HaLow, a low-power wireless technology that enables connections up to one kilometer, making it suitable for a variety of applications including home automation, industrial process control, logistics, surveillance systems, and asset management. The company was established by a team of Wi-Fi innovators and is backed by a strong portfolio of intellectual property and patents, facilitating extensive connectivity across the IoT ecosystem. Morse Micro also has offices in China and the United States, enhancing its global reach and capabilities in the wireless technology market.
Agerris is a field robotics and AI start-up for the agriculture industry, based on technology created at the Australian Centre for Field Robotics, the University of Sydney, where they have been developing air and ground robotic solutions for the agriculture industry since 2005.
Agerris is a field robotics and AI start-up for the agriculture industry, based on technology created at the Australian Centre for Field Robotics, the University of Sydney, where they have been developing air and ground robotic solutions for the agriculture industry since 2005.
Forcite Helmet Systems Pty Ltd, established in 2013 and located in Haymarket, Australia, specializes in the production of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation capabilities, intercom functionality, and active noise-cancelling technology. By utilizing sensor technology and the Forcite Command software platform, the company aims to significantly improve the safety of motorcyclists, addressing the challenges posed by the lack of standard safety equipment in motorcycles compared to modern vehicles. The use of lightweight carbon fiber further contributes to the innovative design and performance of their helmets, making motorcycling safer and more connected.
Forcite Helmet Systems Pty Ltd, established in 2013 and located in Haymarket, Australia, specializes in the production of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation capabilities, intercom functionality, and active noise-cancelling technology. By utilizing sensor technology and the Forcite Command software platform, the company aims to significantly improve the safety of motorcyclists, addressing the challenges posed by the lack of standard safety equipment in motorcycles compared to modern vehicles. The use of lightweight carbon fiber further contributes to the innovative design and performance of their helmets, making motorcycling safer and more connected.
Wildlife Drones Pty. Ltd., founded in 2016 and based in Macquarie, Australia, specializes in designing and developing advanced animal radio-tracking systems utilizing drones. The company addresses the challenges faced by wildlife researchers in tracking the movements of radio-tagged animals, particularly those that are highly mobile. Traditional ground-based tracking often requires elevated positions, making it labor-intensive and costly, as it may involve using helicopters or planes to receive clear signals. Wildlife Drones' innovative technology enhances the quality and quantity of radio-tracking data by allowing drones to reach greater altitudes. This capability supports a range of applications for wildlife researchers, conservationists, and environmental consultants, including the monitoring of endangered species, tracking invasive species, and locating livestock on remote properties, thereby aiding efforts to minimize environmental impact.
PERKii Pty Ltd specializes in producing probiotic beverages that combine 85% water with natural flavors and juice. Founded in 2015 and based in Saint Lucia, Australia, the company offers a range of refreshing drinks available in five flavors: Raspberry & Pomegranate, Elderflower & Green Tea, Lime & Coconut, Strawberry & Watermelon, and Mango & Passionfruit. Each beverage contains only 26 calories and a minimal amount of sugar derived from apples. PERKii utilizes a unique Progel™ technology developed by scientists at The University of Queensland, which encapsulates probiotics in microgels to ensure their survival through the digestive system, enhancing their effectiveness. The products are sold through both retail and online channels, positioning PERKii as a leader in the health-focused beverage market.
Exonate Limited is a biotechnology company focused on the discovery and development of small molecule drugs that target alternative mRNA splicing, specifically in the field of ophthalmology. Founded in 2013 and based in Duxford, United Kingdom, with a research laboratory in Nottingham, Exonate is dedicated to addressing conditions such as diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), which are significant causes of vision loss. The company's lead program aims to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) by selectively targeting the splicing mechanisms mediated by serine/threonine-protein kinase 1 (SRPK1). Exonate has developed a pipeline of small molecule inhibitors that have shown promising efficacy in preclinical models. The company has completed an optimization program supported by the Wellcome Trust, leading to the nomination of a pre-clinical candidate drug. Exonate is guided by an experienced management team with expertise in medicine and drug development, and it aims to apply for regulatory evaluation to advance its therapeutic candidates into clinical trials.
Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Nexgen is an emerging plant trait company delivering non-GM solutions for a range of pathogens, production traits and consumer traits. Our solutions help agriculture-dependent communities around the world improve returns and respond rapidly to emerging opportunities and challenges. The proprietary transformation technique is developing crops that are virus-resistant; fungal-resistant; salt-tolerant; high in anthocyanin content; and aromatic. These solutions are developing the next generation of globally valued crops for food, fibre, energy and ornamentation.
Developer of an operational management platform designed to help with third-party workflow optimization. The company's platform helps to monitor supplier lifecycle management to the customer and partner validation, enabling businesses to manage risk, compliance, and operations of all third parties globally in one place.
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Cardihab provides clinicians with the ability to remotely deliver a scientifically validated, comprehensive Phase 2 CR program based on ACRA guidelines. In a world first randomised controlled trial, CSIRO & Queensland Health researchers demonstrated that remote delivery of CR improves patient uptake (+29%), adherence (+38%) and completion (+70%) while significantly reducing the number of centre visits (-86%) and delivering equivalent clinical outcomes when compared to traditional, centre-based Phase 2 rehab program.
Cardihab provides clinicians with the ability to remotely deliver a scientifically validated, comprehensive Phase 2 CR program based on ACRA guidelines. In a world first randomised controlled trial, CSIRO & Queensland Health researchers demonstrated that remote delivery of CR improves patient uptake (+29%), adherence (+38%) and completion (+70%) while significantly reducing the number of centre visits (-86%) and delivering equivalent clinical outcomes when compared to traditional, centre-based Phase 2 rehab program.
Brisbane Materials aims to be the leading supplier of anti-reflective and anti-soiling coatings for solar and other applications. Born out of the University of Queensland in 2005, Brisbane Materials builds on six years and significant investment in technology and application experience. Longer term, Brisbane Materials will extend its unique room temperature and atmospheric pressure synthesis of glass and ceramic coatings to a wide variety of materials systems and applications.
QUE Oncology, Inc. engages in drug development and therapies for treatment of cancer, such as breast cancer and prostate cancer. The company licenses intellectual property in the areas of scientific research. The company was founded in 2013 and is based in Atlanta, Georgia.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Smart Sparrow owns and operates an e-learning platform, which enables students and professionals to create an e-learning courseware. It allows customers to create courseware on various subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, orientation, sciences, and soft skills, as well as training courses.
Smart Sparrow serves various institutions locally and internationally. Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson founded it on December 29, 2010, with its headquarters in Surry Hills in Australia with an additional office in San Francisco in California.
Smart Sparrow owns and operates an e-learning platform, which enables students and professionals to create an e-learning courseware. It allows customers to create courseware on various subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, orientation, sciences, and soft skills, as well as training courses.
Smart Sparrow serves various institutions locally and internationally. Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson founded it on December 29, 2010, with its headquarters in Surry Hills in Australia with an additional office in San Francisco in California.
Exonate Limited is a biotechnology company focused on the discovery and development of small molecule drugs that target alternative mRNA splicing, specifically in the field of ophthalmology. Founded in 2013 and based in Duxford, United Kingdom, with a research laboratory in Nottingham, Exonate is dedicated to addressing conditions such as diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), which are significant causes of vision loss. The company's lead program aims to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) by selectively targeting the splicing mechanisms mediated by serine/threonine-protein kinase 1 (SRPK1). Exonate has developed a pipeline of small molecule inhibitors that have shown promising efficacy in preclinical models. The company has completed an optimization program supported by the Wellcome Trust, leading to the nomination of a pre-clinical candidate drug. Exonate is guided by an experienced management team with expertise in medicine and drug development, and it aims to apply for regulatory evaluation to advance its therapeutic candidates into clinical trials.
PERKii Pty Ltd specializes in producing probiotic beverages that combine 85% water with natural flavors and juice. Founded in 2015 and based in Saint Lucia, Australia, the company offers a range of refreshing drinks available in five flavors: Raspberry & Pomegranate, Elderflower & Green Tea, Lime & Coconut, Strawberry & Watermelon, and Mango & Passionfruit. Each beverage contains only 26 calories and a minimal amount of sugar derived from apples. PERKii utilizes a unique Progel™ technology developed by scientists at The University of Queensland, which encapsulates probiotics in microgels to ensure their survival through the digestive system, enhancing their effectiveness. The products are sold through both retail and online channels, positioning PERKii as a leader in the health-focused beverage market.
MetaBloQ Pty Ltd is a biotechnology company based in Melbourne, Australia, specializing in the development of innovative drugs aimed at treating challenging cancers, including triple-negative breast cancer, prostate cancer, and melanoma. Founded in 2016, the company focuses on discovering and developing therapies that target specific metabolic processes within cancer cells, with the goal of minimizing toxicity to non-cancerous cells. Through its research and development efforts, MetaBloQ aims to provide patients with safer and more effective treatment options, enhancing their overall quality of life during cancer therapy.
OccuRx Pty. Ltd., a biopharmaceutical company, engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. It has a library of chemical compounds with potent anti-inflammatory and anti-fibrotic properties to treat diabetic retinopathy and other fibrotic diseases of the retina. The company was incorporated in 2013 and is based in Melbourne, Australia.
ProGel is a start-up company from the University of Queensland commercialising a revolutionary method of encapsulating active ingredients for inclusion in foods, cosmetics or pharmaceuticals. In certain applications ProGel allows for the first time encapsulated high value additives small enough to remain undetectable by the consumer, whilst still being cost effective to the manufacturer of the ingredients.
This technology can make dry and liquid stable microgels, with the initial product targets being functional foods such as probiotic drinks or yoghurts, or omega-3 fatty acid enhanced foods. Multi-billion dollar markets have grown around each of these additives, and importantly they are each growing at above 10% per year.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
Nexgen is an emerging plant trait company delivering non-GM solutions for a range of pathogens, production traits and consumer traits. Our solutions help agriculture-dependent communities around the world improve returns and respond rapidly to emerging opportunities and challenges. The proprietary transformation technique is developing crops that are virus-resistant; fungal-resistant; salt-tolerant; high in anthocyanin content; and aromatic. These solutions are developing the next generation of globally valued crops for food, fibre, energy and ornamentation.
Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Smart Sparrow owns and operates an e-learning platform, which enables students and professionals to create an e-learning courseware. It allows customers to create courseware on various subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, orientation, sciences, and soft skills, as well as training courses.
Smart Sparrow serves various institutions locally and internationally. Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson founded it on December 29, 2010, with its headquarters in Surry Hills in Australia with an additional office in San Francisco in California.
Otifex Therapeutics Pty Ltd is an emerging Australian specialty pharmaceutical company developing a new treatment for the most common cause of acquired hearing loss in childhood, Otitis Media with Effusion (OME or “glue ear”). Treating OME often means surgically inserting “grommets” (tympanostomy tubes) to help return middle ear pressure to normal; there are currently no non-invasive alternatives. Otifex is developing a novel nasal spray to make it easier for the ears to ‘pop’, improving middle ear pressure and helping OME resolve naturally. Our product has the potential to be the first effective non-surgical treatment for OME.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
BT Imaging is the market leader for electrical-inspection equipment used in the manufacturing of silicon blocks, silicon solar wafers and silicon solar cells.
ProGel is a start-up company from the University of Queensland commercialising a revolutionary method of encapsulating active ingredients for inclusion in foods, cosmetics or pharmaceuticals. In certain applications ProGel allows for the first time encapsulated high value additives small enough to remain undetectable by the consumer, whilst still being cost effective to the manufacturer of the ingredients.
This technology can make dry and liquid stable microgels, with the initial product targets being functional foods such as probiotic drinks or yoghurts, or omega-3 fatty acid enhanced foods. Multi-billion dollar markets have grown around each of these additives, and importantly they are each growing at above 10% per year.
Manjrasoft Pty. Ltd. is a Melbourne-based company that specializes in commercializing grid and cloud computing software technologies developed by the Grid Computing and Distributed Systems Laboratory. Founded in 2008, the company provides Aneka, a platform designed for rapid application development and workload distribution, which enhances the performance of software applications requiring high computational power. Manjrasoft offers various solutions, including distributed 3D rendering using Autodesk Maya, educational and training tools, and cloud computing consultancy services. The company serves diverse sectors such as engineering, entertainment, gaming, life sciences, and finance, enabling organizations to efficiently build, accelerate, and manage their applications and cloud environments.
Fibrotech Therapeutics develops and offers novel drug candidates for the treatment of fibrosis in chronic conditions. It develops drugs for kidney diseases, diabetics, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006, Fibrotech Therapeutics is based in Wonga Park, Australia.
BT Imaging is the market leader for electrical-inspection equipment used in the manufacturing of silicon blocks, silicon solar wafers and silicon solar cells.
Pepfactants
Series B in 2007
Pepfactants has developed a new way to break apart industrial emulsions, including those found in oil & gas operations, environmental remediation and other manufacturing processes. The company has discovered a chemical additive for demulsify the emulsions, where the additive is cheaper than many alternatives, and withstands extreme levels of salt and other contaminants. The chemical is readily available today as it is used for other, unrelated applications.
Fultec Semiconductor operates as a circuit protection semiconductor company. It offers transient blocking device for the over-voltage and over-current protection of telecommunication and data communication systems. The company's products offer wide bandwidth circuit protection against lightning, power induction, power cross, and short circuit events. Its products have applications, such as telecom, datacom, sensors, automotive, and power distribution. The company was founded in 2001 and is headquartered in Mountain View, California. As of October 13, 2008, Fultec Semiconductor, Inc. operates as a subsidiary of Bourns, Inc.
OPAL Therapeutics
Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
QRxPharma Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative pain management and abuse prevention products. Based in Camberwell, Australia, the company emphasizes enhancing the clinical utility of existing compounds while introducing new solutions to the market. Its product portfolio includes both late and early-stage drug candidates, particularly the immediate release MOXDUO®, a dual opioid formulation combining morphine and oxycodone, aimed at treating acute pain. QRxPharma also features Stealth Beadlets™, a proprietary abuse-deterrent technology applicable to solid dosage forms. The company has established strategic partnerships for the commercialization of MOXDUO in various regions, including the United States, Canada, Australia, and South Africa. Additionally, it is collaborating with Aesica Formulation Development Limited to promote its abuse deterrence technology. While QRxPharma has faced challenges in its operations, it remains committed to advancing its product pipeline and improving patient outcomes.